Abstract
Amyotrophic lateral sclerosis (ALS) is a difficult disease to study as it is mostly sporadic and rapidly progressive. Identification of genes causing familial ALS (FALS) has been instrumental in advancing our understanding of ALS pathogenesis, most notably with the use of mutant superoxide dismutase 1 (SOD1) models of disease. For 15 years SOD1 models have been the backbone of ALS research, but no effective treatments have been developed. However, recent advances have been made in the genetics of ALS with the identification of mutations in TAR DNA binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS), both of which have roles in RNA-processing and gene expression. Molecular links between ALS and frontotemporal dementia (FTD) are also suggested by linkage of ALS-FTD to chromosome 9. The study of the genetics of sporadic ALS (SALS) has been less fruitful, although this may change as we enter the era of resequencing. Further important clues as to the causes of ALS will come from the identification of other gene mutations that cause FALS, variants that increase susceptibility to SALS, and genetic factors that modify the ALS phenotype.
Keywords: Amyotrophic Lateral Sclerosis, Genetics, TDP-43, FUS
CNS & Neurological Disorders - Drug Targets
Title: Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
Volume: 9 Issue: 3
Author(s): J. Sreedharan
Affiliation:
Keywords: Amyotrophic Lateral Sclerosis, Genetics, TDP-43, FUS
Abstract: Amyotrophic lateral sclerosis (ALS) is a difficult disease to study as it is mostly sporadic and rapidly progressive. Identification of genes causing familial ALS (FALS) has been instrumental in advancing our understanding of ALS pathogenesis, most notably with the use of mutant superoxide dismutase 1 (SOD1) models of disease. For 15 years SOD1 models have been the backbone of ALS research, but no effective treatments have been developed. However, recent advances have been made in the genetics of ALS with the identification of mutations in TAR DNA binding protein (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS), both of which have roles in RNA-processing and gene expression. Molecular links between ALS and frontotemporal dementia (FTD) are also suggested by linkage of ALS-FTD to chromosome 9. The study of the genetics of sporadic ALS (SALS) has been less fruitful, although this may change as we enter the era of resequencing. Further important clues as to the causes of ALS will come from the identification of other gene mutations that cause FALS, variants that increase susceptibility to SALS, and genetic factors that modify the ALS phenotype.
Export Options
About this article
Cite this article as:
Sreedharan J., Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?, CNS & Neurological Disorders - Drug Targets 2010; 9 (3) . https://dx.doi.org/10.2174/187152710791292558
DOI https://dx.doi.org/10.2174/187152710791292558 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Preliminary Study of the Action of Virtosomes from Non-dividing Cells on Tumour Cell Replication in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Differences and Similarities of Epothilones
Current Cancer Therapy Reviews Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets Biosafety of Herpesvirus Vectors
Current Gene Therapy The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial (Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites – Part II A)
Current Medicinal Chemistry Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Mesenchymal Stem Cell Therapy for Equine Tendinitis
Recent Patents on Regenerative Medicine Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Chromatin Structure and Epigenetics of Tumour Cells: A Review
Cardiovascular & Hematological Disorders-Drug Targets Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry Copper(II) Complexes with Saccharinate and Glutamine as Antitumor Agents: Cytoand Genotoxicity in Human Osteosarcoma Cells
Anti-Cancer Agents in Medicinal Chemistry Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Protein & Peptide Letters Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Antiangiogenic Therapy
Current Pharmaceutical Design Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine